This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wake Up to These 2 Opportunities

NEW YORK (TheStreet) -- When I was a boy I remember my grandfather spending a couple of weeks at our family home. Before going to bed he would always fill a little shot glass with some gold-colored liquid from a bottle with a man's name (Jack Daniels) on it.

When I asked him why he'd say, "It helps me fall asleep." When I became a teenager I learned what that gold-colored liquid was that Grandpa used it for his nightly insomnia. My personal struggles with sleep are different than Grandpa's. I can fall asleep without much assistance, but I have trouble staying asleep.

My doctor diagnosed me with a "sleep-disordered breathing" condition and suggested that I try a bi-level, continuous positive airway pressure (CPAP) machine. Now I can't sleep without it.

One of the machines I've used and benefited from is made by ResMed (RMD), and I've since learned it's an industry-leading company with lots of positive momentum.

RMD is a profitable developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB) and other respiratory disorders. The company's Web site declares the company is "...dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing."

Millions suffer from SBD and, as ResMed's Web site states emphatically, "SDB affects around 20% of the adult population, making it as widespread as diabetes or asthma. However, awareness is low and we believe that about 90% of people who have OSA remain undiagnosed and untreated."

This is a very serious, life-threatening challenge, and SBD is most commonly related with a condition called "sleep apnea." RMD's Web site explains the opportunities: "Along with an increasing understanding of the morbidity and mortality caused by SDB, this discrepancy has created one of the fastest growing segments of the respiratory industry. ResMed is positioned to meet the growing challenges of this under-penetrated market."

This may help explain why RMD's year-over-year quarterly earnings growth was a remarkable 41%. The stock, which closed on Tuesday, at $40.86, is selling for less than 18 times forward (one-year earnings). Yet, its price-to-earnings-to-growth (PEG) ratio (five-year expected) is only 1.06. This indicates shares are still undervalued.

Take a look at the one-year price chart with its skyrocketing diluted EPS growth rate. RMD ChartRMD data by YCharts

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs